PRO/CON Chul Soo Ha, MD If systemic treatment is effective enough to reliably control not only microscopic but also bulky disease, there will be little role for radiotherapy. And if systemic treatment cannot even reliably control microscopic disease, let alone macroscopic disease, there will be little role for radiotherapy, either.
PRO/CON Soham Puvvada, MD, Thomas Miller, MD DLBCL of any stage remains a systemic disease with early hematogenous spread. Thus, arguments advocating the role of IFRT do not truly address disease biology, and all future efforts to cure patients will require improved systemic therapy.
RESEARCH REPORT Anna Azvolinsky Researchers have characterized acute myeloid leukemia, providing new genetic driver leads to help classify the disease and even stratify AML patients by risk.
RESEARCH REPORT Michael Kaufman A dose-adjusted regimen of etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH-R) obviated the need for radiotherapy in patients with primary mediastinal B-cell lymphoma in a single-group, phase II, prospective study.
RESEARCH REPORT Anna Azvolinsky Researchers have identified a novel monoclonal antibody directly targeted against a receptor found in abundance on chronic lymphocytic leukemia (CLL) cells, but not normal B cells. The humanized antibody can directly kill CLL cells.
RESEARCH REPORT Michael Kaufman Targeting the bone marrow–specific extracellular matrix osteopontin may be an effective strategy to increase the efficacy of chemotherapy in patients with acute lymphocytic leukemia, according to the authors of a recent study.
REVIEW ARTICLE Shadi Latta, et al;ONCOLOGY Vol. 27 No. 2 In this review, we critically analyze clinical trials that were specifically designed for the very elderly, and we discuss the challenges encountered by investigators who are conducting studies in this patient population.
Primary central nervous system lymphomas, predominantly diffuse large B-cell lymphomas (PCNS-DLBCL), are aggressive malignancies, and no histopathological variables with independent prognostic value are currently available. The aim of this study is to determine the prognostic value of histopathological variables of PCNS-DLBCL.
Methods
Aggregative perivascular tumor cells (APVTs) and reactive perivascular T cell infiltrates (RPVIs) in tumor samples from 6
The alkylating agent temozolomide (TMZ) is widely used for the treatment of gliomas. Although reports of treatment-related myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) associated with TMZ are accumulating, it remains unclear whether TMZ has the same leukemogenic potential as other alkylating agents.
Methods
We performed a single-institution retrospective analysis using a database of 359 glioma patie
The optimal treatment strategy in patients with aggressive B cell central nervous system lymphoma suitable to receive intensive therapy is unknown. The benefit of incorporating rituximab in systemic therapy remains unclear. We performed a retrospective study examining the impact of rituximab in the context of concomitant therapies, including methotrexate, cytarabine, and radiotherapy, in patients treated with curative intent at 4 university teaching hospitals during 1996–2
The standard of care for primary central nervous system lymphoma (PCNSL) is systemic chemotherapy with or without whole brain radiotherapy or intrathecal chemotherapy. In contrast to treatment for other brain tumors, efforts at resection are discouraged. This is a secondary analysis of the German PCNSL Study Group–1 trial, a large randomized phase III study comprising 526 patients with PCNSL. Progression-free survival (hazard ratio [HR]: 1.39; 95% confidence interval [CI]: 1.10–1.74; P<
Although most children treated for acute lymphoblastic leukemia (ALL) survive, the noncognitive neurologic sequelae of ALL treatment are inadequately described, and most reported studies utilize self-administered questionnaires. We undertook a prospective, IRB-approved, cross-sectional study to define neurologic morbidity in ALL survivors who were more than 5 years from diagnosis. An investigator administered the questionnaire and disability scales, and a board-certified neurologist performed a quanti
DLBCL of any stage remains a systemic disease with early hematogenous spread. Thus, arguments advocating the role of IFRT do not truly address disease... More »
Researchers have identified a novel monoclonal antibody directly targeted against a receptor found in abundance on chronic lymphocytic leukemia (CLL)... More »
In this review, we critically analyze clinical trials that were specifically designed for the very elderly, and we discuss the challenges encountered... More »
A genome-wide study, and analysis of genes in Reed-Sternberg cells, suggest molecular subtypes that should lead to better therapies and prognostic... More »
Richter's transformation, or Richter's syndrome, is an uncommon clinicopathological condition observed in about 5% to 10% of patients with chronic... More »
DLBCL of any stage remains a systemic disease with early hematogenous spread. Thus, arguments advocating the role of IFRT do not truly address disease biology, and all future efforts to cure patients will require improved systemic therapy.
If systemic treatment is effective enough to reliably control not only microscopic but also bulky disease, there will be little role for radiotherapy. And if systemic treatment cannot even reliably control microscopic disease, let alone macroscopic disease, there will be little role for radiotherapy, either. However, there are patients who fall into neither of these categories, and in them radiotherapy may well have a role.
In this interview we discuss the latest chronic myeloid leukemia treatment and research with Dr. Michael Deininger, chief of the division of hematology at the University of Utah School of Medicine.
A 53-year-old woman presented with abominal pain. Physical examination and radiographic imaging shows the presence of an abdominal mass. Biopsy of the mass was performed. What is your diagnosis?
Primary Care Can't Thrive Without Nurse Practitioners Courtney H. Lyder, ND, May 17, 2013 With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
In this review, we critically analyze clinical trials that were specifically designed for the very elderly, and we discuss the challenges encountered by investigators who are conducting studies in this patient population. We conclude by proposing an algorithm to help clinicians determine the optimal therapeutic strategy for treatment of DLBCL in very elderly patients.
In Hodgkin lymphoma, as with many other malignancies, a combined-modality approach has proven successful. This tactic capitalizes on the relative advantages of both modalities, yet minimizes risk by avoiding intense exposure to either. This article will summarize the data supporting this approach in early-stage Hodgkin lymphoma.
This review will discuss the pathophysiology associated with the del(17p13.1) interphase cytogenetic abnormality, the current generally poor outcomes in affected patients, currently approved therapeutic agents, and new agents now undergoing investigation.
Is it reasonable to start all new CML patients on treatment with imatinib alone and continue the drug indefinitely in those who fare well, or should one start treatment with one of the newer agents or possibly with imatinib in combination with another anti-CML agent in order to secure the best possible outcome for an individual patient?
In this review, we will discuss the management of ALL in the adult population, in the context of the recently published guidelines from the NCCN. We will focus in particular on the strides being made in salvage and targeted approaches.
Although the overall prognosis for patients with acute myeloid leukemia (AML) associated with unfavorable, complex, or monosomal karyotypes is poor, some patients can be cured.
The treatment of APL in the modern era is a success of modern hematology. In this review we have attempted to plant the seeds of understanding regarding how diagnosis and treatment of APL will be pursued over the next decade.
This article examines clinical and biological features of DLBCL patients with poor outcomes, and reviews recent studies addressing alternatives to standard front-line management strategies together with unresolved questions.
This review addresses the rationale and evidence for—and the challenges, cost implications, and future development of—proton therapy as an important part of the treatment strategy in Hodgkin lymphoma.
In this interview we discuss the latest chronic myeloid leukemia treatment and research with Dr. Michael Deininger, chief of the division of hematology at the University of Utah School of Medicine.
Hematology Letters is a new blog for Cancer Network written by Mojtaba Akhtari, MD of the University of Nebraska Medical Center, Omaha, Nebraska.
A 53-year-old woman presented with abominal pain. Physical examination and radiographic imaging shows the presence of an abdominal mass. Biopsy of the mass was performed. What is your diagnosis?
